Shafrir Amy L, Rice Megan S, Gupta Mamta, Terry Kathryn L, Rosner Bernard A, Tamimi Rulla M, Hecht Jonathan L, Tworoger Shelley S
Department of Epidemiology, Harvard TH Chan School of Public Health, 677 Huntington Ave, Boston, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Ave, Boston, MA, USA.
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Ave, Boston, MA, USA; Clinical and Translation Epidemiology Unit, Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, USA.
Gynecol Oncol. 2016 Dec;143(3):628-635. doi: 10.1016/j.ygyno.2016.09.024. Epub 2016 Oct 5.
We assessed the association between reproductive and hormonal factors and ovarian cancer incidence characterized by estrogen receptor-α (ERα) and progesterone receptor (PR) status.
Tissue microarrays were used to assess ERα and PR expression among 197 Nurses' Health Study (NHS), 42 NHSII and 76 New England Case-Control Study (NECC) ovarian cancer cases. NHS/NHSII cases were matched to up to 4 controls (n=954) on diagnosis date and birth year. NECC controls (n=725) were frequency matched on age. Cases were considered receptor positive if ≥1% of tumor cells stained positive. Associations by ERα and PR status were assessed using polytomous logistic regression. p-Value for heterogeneity was calculated using a likelihood ratio test.
45% of ovarian tumors were PR(+), 78% were ERα(+) and 45% were ERα(+)/PR(+), while 22% were ERα(-)/PR(-). Postmenopausal status was associated with an increased risk of PR(-) tumors (OR: 2.07; 95%CI: 1.15-3.75; p-heterogeneity=0.01) and age at natural menopause was inversely associated with PR(-) tumors (OR, per 5years: 0.77; 95%CI: 0.61-0.96; p-het=0.01). Increasing duration of postmenopause was differentially associated by PR status (p-het=0.0009). Number of children and tubal ligation were more strongly associated with ERα(-) versus ERα(+) tumors (p-het=0.002 and 0.05, respectively). No differential associations were observed for oral contraceptive or hormone therapy use.
Postmenopausal women have an increased risk of developing PR(-) ovarian tumors compared to premenopausal women. The associations observed for ovarian cancer differ from those seen for breast cancer suggesting that the biology for tumor development through ERα and PR pathways may differ.
我们评估了生殖和激素因素与以雌激素受体-α(ERα)和孕激素受体(PR)状态为特征的卵巢癌发病率之间的关联。
使用组织微阵列评估197例护士健康研究(NHS)、42例NHSII和76例新英格兰病例对照研究(NECC)卵巢癌病例中的ERα和PR表达。NHS/NHSII病例在诊断日期和出生年份上与多达4名对照(n = 954)进行匹配。NECC对照(n = 725)按年龄进行频率匹配。如果≥1%的肿瘤细胞染色呈阳性,则病例被视为受体阳性。使用多分类逻辑回归评估按ERα和PR状态的关联。使用似然比检验计算异质性的p值。
45%的卵巢肿瘤为PR(+),78%为ERα(+),45%为ERα(+)/PR(+),而22%为ERα(-)/PR(-)。绝经后状态与PR(-)肿瘤风险增加相关(OR:2.07;95%CI:1.15 - 3.75;p异质性 = 0.01),自然绝经年龄与PR(-)肿瘤呈负相关(OR,每5年:0.77;95%CI:0.61 - 0.96;p异质性 = 0.01)。绝经后持续时间的增加与PR状态存在差异关联(p异质性 = 0.0009)。与ERα(+)肿瘤相比,子女数和输卵管结扎与ERα(-)肿瘤的关联更强(p异质性分别为0.002和0.05)。在口服避孕药或激素治疗使用方面未观察到差异关联。
与绝经前女性相比,绝经后女性发生PR(-)卵巢肿瘤的风险增加。观察到的卵巢癌关联与乳腺癌不同,这表明通过ERα和PR途径发生肿瘤的生物学机制可能不同。